Our offerings

There is rarely a perfect solution in Market Access – but we can help you with the best possible solution.

There’s no one-size-fits-all approach to market access. Different technologies, different patients, different trial setups , different landscapes. All of this impacts what the optimal market access strategy looks like . And to make matters worse, what works in one country or region may not work elsewhere.

We understand the important nuances and provide market access strategies that factor in the local requirements, the attributes of the technology, evidence, positioning, and the evolving pricing & reimbursement landscapes to help you chose the optimal solution.

And with more than 10 years of experience within this field, we have the cases to prove this!

The quality of your HTA submission determines the likelihood of your access success!

Even though guidelines for HTA submissions are often very strict, it does not mean that the results are a foregone conclusion. Here, it is particularly important to think outside the box to ensure all the relevant elements of value are captured and that the value story has a clear red thread. This is extremely difficult when you do not have many years of successful experience within this.

Don’t worry – with 10+ years of experience in Nordic HTA submissions, we are specialist in this. We know what to consider, how to consider it, and how to optimally present it.

Why NHTA is your partner to show the value of your technology through health economics

There’s no getting around it. Health economics are here to stay!

By now, we all know that the health economics in most cases is equally as important as the clinical value.

However, did you know that health economic models can be methodologically rigorous, while still illustrating and focusing on the value of your technology?

That perfect balance is what we Excel at! (Pun intended)

We are guided by our backgrounds in HTA and Payers organisations, the Pharma- and MedTech industry to ensure this. Combine that with our 8+ year experience in supporting clients with 200+ bespoke models and model adaptations and you have a unique recipe.

But first, we need to understand your needs and objectives to determine the best solution for you!

Does your clinical evidence answer the right questions?

Evidence is still king, and clinical trials remain the gold standard—but the landscape is evolving.

Regulatory agencies and local HTA bodies are raising the bar, demanding more nuanced and comprehensive evidence. This includes robust subgroup analyses, credible indirect treatment comparisons, and strategies to address data gaps, missing comparators, trial heterogeneity, and the challenge of transferring results to local healthcare settings.

Evidence generation isn’t a one-off task—it’s a dynamic, ongoing process. To meet evolving regulatory and market demands, your evidence plan must adapt over time, supporting various stakeholder needs across the product lifecycle.

We combine deep expertise within clinical research, real-world evidence, health economics, statistics, market access, and pricing.

We partner with you to build a robust, tailored evidence generation strategy that utilise the best possible evidence to maximize your product’s potential.